期刊
CELLULAR AND MOLECULAR LIFE SCIENCES
卷 74, 期 9, 页码 1681-1692出版社
SPRINGER BASEL AG
DOI: 10.1007/s00018-016-2430-8
关键词
Biotherapeutics; eIF4F; eIF4A; 4EBP; PDCD4; Translational control; Antisense; Cancer therapeutics
资金
- Charlotte and Leo Karassik Postdoctoral Fellowship
- Canadian Institutes of Health Research [CIHR] [G243873]
Biotherapeutics have revolutionized modern medicine by providing medicines that would not have been possible with small molecules. With respect to cancer therapies, this represents the current sector of the pharmaceutical industry having the largest therapeutic impact, as exemplified by the development of recombinant antibodies and cell-based therapies. In cancer, one of the most common regulatory alterations is the perturbation of translational control. Among these, changes in eukaryotic initiation factor 4F (eIF4F) are associated with tumor initiation, progression, and drug resistance in a number of settings. This, coupled with the fact that systemic suppression of eIF4F appears well tolerated, indicates that therapeutic agents targeting eIF4F hold much therapeutic potential. Here, we discuss opportunities offered by biologicals for this purpose.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据